Skip to main content
Premium Trial:

Request an Annual Quote

Genetic MicroSystems Will Operate from an Expanded Facility

Premium

WOBURN, Mass.--Genetic MicroSystems announced it will begin operating in a new 30,000-square-foot facility here next week. The company, founded in 1997, is developing enabling products for genomics research and drug discovery based on a technology platform that includes proprietary approaches to creating arrays on solid supports, rapidly viewing wide fields with high resolution, and related software consumables. Its first product will be a high-performance, low-cost DNA-array-making instrument featuring high speed, consistent spot size, and high repeatability. The company also said it plans to leverage other aspects of its proprietary technology platform by producing WFMTM systems that can capture digital images of surfaces the size of a microscope slide, with submicron resolution, in times ranging from seconds to minutes. Such systems will drive the widespread use of biochip technology in genomics research, make possible rapid rare event detections for microbiological analyses, and facilitate the implementation of virtually real-time telepathology, the company said.

Filed under

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.